Literature DB >> 11012391

Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir.

X Duval, V Le Moing, C Longuet, C Leport, J L Vildé, C Lamotte, G Peytavin, R Farinotti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11012391      PMCID： PMC90119          DOI： 10.1128/AAC.44.9.2593-2593.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  5 in total

1.  Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.

Authors:  D J Livington; S Pazhanisamy; D J Porter; J A Partaledis; R D Tung; G R Painter
Journal:  J Infect Dis       Date:  1995-11       Impact factor: 5.226

2.  Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.

Authors:  B M Sadler; C D Hanson; G E Chittick; W T Symonds; N S Roskell
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 3.  Efavirenz.

Authors:  J C Adkins; S Noble
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

Review 4.  Amprenavir.

Authors:  J C Adkins; D Faulds
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

Review 5.  Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.

Authors:  A Hsu; G R Granneman; R J Bertz
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447
  5 in total
  11 in total

1.  Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.

Authors:  Elke Störmer; Lisa L von Moltke; Michael D Perloff; David J Greenblatt
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

Review 2.  Pharmacokinetic enhancement of protease inhibitor therapy.

Authors:  Jennifer R King; Heather Wynn; Richard Brundage; Edward P Acosta
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 3.  Amprenavir: a review of its clinical potential in patients with HIV infection.

Authors:  S Noble; K L Goa
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

4.  Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals.

Authors:  Gene D Morse; Susan Rosenkranz; Michael F Para; Yoninah Segal; Robin Difrancesco; Elizabeth Adams; Barbara Brizz; Kevin E Yarasheski; Richard C Reichman
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.

Authors:  P F Smith; R DiCenzo; G D Morse
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.

Authors:  Xavier Duval; Claire Lamotte; Ester Race; Diane Descamps; Florence Damond; François Clavel; Catherine Leport; Gilles Peytavin; Jean-Louis Vilde
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

7.  Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.

Authors:  Ivy Song; Julie Borland; Sherene Min; Yu Lou; Shuguang Chen; Parul Patel; Toshihiro Wajima; Stephen C Piscitelli
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

Review 8.  Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.

Authors:  Cédric Arvieux; Olivier Tribut
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.

Authors:  Cecile Goujard; Isabelle Vincent; Jean-Luc Meynard; Nathalie Choudet; Diane Bollens; Cyril Rousseau; Didier Demarles; Catherine Gillotin; Roselyne Bidault; Anne-Marie Taburet
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

10.  Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

Authors:  Anne-Geneviève Marcelin; Claire Lamotte; Constance Delaugerre; Nadine Ktorza; Hocine Ait Mohand; Raquel Cacace; Manuela Bonmarchand; Marc Wirden; Anne Simon; Philippe Bossi; François Bricaire; Dominique Costagliola; Christine Katlama; Gilles Peytavin; Vincent Calvez
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.